ArticleAnnals of medicine and surgery (2012)2025
Integrative AI-metabolomics: a new frontier in diagnosing pulmonary tumor thrombotic microangiopathy.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond CT and MRI: terahertz imaging as a frontier tool for early mesothelioma diagnosis.Annals of medicine and surgery (2012) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, rapidly progressive malignancy-related pulmonary vascular condition that remains difficult to diagnose before death due to its nonspecific clinical and imaging features. Recent advances in metabolomics, particularly when powered by artificial intelligence (AI), offer promising opportunities for early detection by identifying distinct metabolic signatures. While AI-driven metabolomics has shown success in various cancers, its application to PTTM is challenged by the rarity of the disease, limited datasets, and privacy concerns. Innovations such as multicenter collaborations and blockchain-based data sharing may help overcome these barriers. Integrating AI and metabolomics has the potential to revolutionize not only the diagnosis of PTTM but also other rare diseases with elusive early biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.